



# SAVE THE DATE

## Migraine Milestones: A Journey with the AbbVie Medical Institute


Together with Patricia Pozo-Rosich we are thrilled to invite you to join us on our journey with the AbbVie Medical Institute (AMI) bringing new migraine milestone to you. An exciting event that will be making its way to six different cities across Switzerland.

### Here's a sneak peek of what's in store for you:

- In-depth presentation of Aquipta® studies and their application in clinical practice.
- Exploring patient management strategies, with a special focus on goal setting
  - Is good still good enough for your patients?
- Get the chance to engage with experts and ask any burning questions you may have about migraine prophylaxis.



Patricia Pozo-Rosich MD PhD,  
Vall d'Hebron University Hospital  
Barcelona, Spain



key studies



patient management strategies



engage with experts

### Save the dates for the following cities:

- ▶ Lugano : 22.01.2025, 08:00–09:30  
Speaker : Dr Patricia Pozo-Rosich; Co-Chair: Prof.ssa Chiara Zecca
- ▶ Zurich : 22.01.2025, 18:00–19:30  
Speaker : Dr Patricia Pozo-Rosich; Co-Chair: Dr. Reto Agosti
- ▶ Lausanne : 23.01.2025, 12:15–13:45  
Speaker : Dr Patricia Pozo-Rosich; Co-Chair: Prof. Philippe Ryvlin
- ▶ Geneva : 23.01.2025, 17:00–18:30  
Speaker : Dr Patricia Pozo-Rosich; Co-Chair: Prof. Andreas Kleinschmidt
- ▶ Bern : 24.01.2025, 12:00–13:30  
Speaker : Dr Patricia Pozo-Rosich; Co-Chair: Prof. Christoph Schankin
- ▶ Basel : 24.01.2025, 17:00–18:30  
Speaker : Dr Patricia Pozo-Rosich; Co-Chair: PD Dr Athina Papadopoulou

**Credits:** The workshop will be credited with 1 CME points according to SNG

**Sponsors:** This workshop will be co-sponsored by Neurolite.



◀ Please register your interest for this Workshop



To secure your spot, please register using the link provided for each city.

Looking forward to seeing you there!

Best regards,

Your AbbVie Medical Institute Team

#### Succinct summary of product characteristics AQUIPTA®

**I:** Prophylactic treatment of migraine in adults when indicated. **D:** Recommended dose is 60 mg orally once daily; Dose modification to 10 mg daily with concomitant use of strong CYP3A4 inhibitors or OATP inhibitors, or in severe renal impairment and end-stage renal disease. **CI:** Hypersensitivity to the active substance or to any of the excipients. **W:** Not recommended in patients with severe hepatic impairment; No safety data are available for patients with clinically relevant cardiovascular or cerebrovascular disorders. **IA:** When concomitantly used with itraconazole or single dose rifampicin, dose adjustment is recommended due to increased exposure to atogepant; Steady-state rifampicin may reduce exposure to atogepant. **AE:** Common (≥ 1/100): Decreased appetite, weight decreased, nausea, constipation, fatigue/somnolence. **P:** Blisters in packs containing 28 tablets à 10 or 60 mg. List B; reimbursed. **M:** AbbVie AG, Steinhauserstrasse 14, 6330 Cham, Tel. (+41) 41 399 15 00. (V1) For detailed medicinal product's characteristics see: [www.swissmedinfo.ch](http://www.swissmedinfo.ch)